final os analysis of sacituzumab govitecan in tropics-02
Published 1 year ago • 281 plays • Length 1:49Download video MP4
Download video MP3
Similar videos
-
4:38
2nd interim analysis of os from tropics-02: sg in hr /her2- breast cancer
-
1:00
tropics-02: sacituzumab govitecan in hr /her- breast cancer
-
1:34
sacituzumab govitecan effective for hr metastatic breast cancer regardless of trop-2 status
-
1:36
real-word efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer
-
2:01
ascent: sacituzumab govitecan outperforms chemo in black patients with tnbc
-
1:57
monarcher: final os results of abemaciclib in hr , her breast cancer
-
1:08
ascent-05: sacituzumab govitecan and pembrolizumab in tnbc
-
2:15
ascent: sacituzumab govitecan biomarker analysis
-
3:03
it's time for trodelvy
-
8:49
sabcs 2022: results from the phase iii capitello-291 trial
-
10:42
trodelvy trial failed.
-
1:30
final os analysis from arches
-
1:58
ascent-04: sacituzumab govitecan and pembrolizumab in pd-l1-positive tnbc
-
1:48
secombit – determining the order of sequential therapies in metastatic melanoma with braf mutations
-
3:59
sacituzumab govitecan for treatment-refractory metastatic breast cancer
-
3:10
ascent trial: sacituzumab govitecan for tnbc
-
5:37
metastatic breast cancer at esmo 2022: tropics02, monarch 3 and synergy
-
14:47
sacituzumab govitecan clinical pearl
-
5:06
safety outcomes in the phase iii monarche trial of abemaciclib et in hr , her2- breast cancer
-
0:44
adcs in early breast cancer
-
1:09
where are we in sequencing adcs in hr breast cancer?